---
document_datetime: 2025-12-02 05:38:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rituzena.html
document_name: rituzena.html
version: success
processing_time: 0.1147558
conversion_datetime: 2025-12-24 01:45:50.8332
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rituzena (previously Tuxella)

[RSS](/en/individual-human-medicine.xml/66261)

##### Withdrawn

This medicine's authorisation has been withdrawn

rituximab Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rituzena (previously Tuxella)](#news-on)
- [More information on Rituzena](#more-information-on-rituzena-1247)
- [Related content](#related-content-648)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 10 April 2019, the European Commission withdrew the marketing authorisation for Rituzena (rituximab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Celltrion Healthcare Hungary Kft., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Rituzena was granted marketing authorisation in the EU on 13 July 2017 for treatment of nonHodgkin's lymphoma, chronic lymphocytic leukaemia, granulomatosis with polyangiitis and microscopic polyangiitis. The marketing authorisation was initially valid for a 5-year period.

Rituzena is a biosimilar of MabThera. There are other biosimilar medicinal products of MabThera authorised and marketed in the EU. Rituzena was a duplicate application to Truxima, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Truxima and the other duplicates Ritemvia and Blitzima.

The European Public Assessment Report (EPAR) for Rituzena is updated to indicate that the marketing authorisation is no longer valid.

Rituzena : EPAR - Summary for the public

Reference Number: EMA/327752/2017

English (EN) (563.69 KB - PDF)

**First published:** 15/08/2017

**Last updated:** 26/09/2017

[View](/en/documents/overview/rituzena-epar-summary-public_en.pdf)

[Other languages (20)](#file-language-dropdown-552)

български (BG) (642.98 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/bg/documents/overview/rituzena-epar-summary-public_bg.pdf)

español (ES) (562.52 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/es/documents/overview/rituzena-epar-summary-public_es.pdf)

čeština (CS) (646.11 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/cs/documents/overview/rituzena-epar-summary-public_cs.pdf)

dansk (DA) (556.96 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/da/documents/overview/rituzena-epar-summary-public_da.pdf)

Deutsch (DE) (566.2 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/de/documents/overview/rituzena-epar-summary-public_de.pdf)

eesti keel (ET) (555.94 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/et/documents/overview/rituzena-epar-summary-public_et.pdf)

ελληνικά (EL) (673.11 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/el/documents/overview/rituzena-epar-summary-public_el.pdf)

français (FR) (564.76 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/fr/documents/overview/rituzena-epar-summary-public_fr.pdf)

hrvatski (HR) (582.65 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/hr/documents/overview/rituzena-epar-summary-public_hr.pdf)

italiano (IT) (556.72 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/it/documents/overview/rituzena-epar-summary-public_it.pdf)

latviešu valoda (LV) (625.82 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/lv/documents/overview/rituzena-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (587.83 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/lt/documents/overview/rituzena-epar-summary-public_lt.pdf)

Malti (MT) (630.65 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/mt/documents/overview/rituzena-epar-summary-public_mt.pdf)

Nederlands (NL) (561.07 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/nl/documents/overview/rituzena-epar-summary-public_nl.pdf)

polski (PL) (642.28 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/pl/documents/overview/rituzena-epar-summary-public_pl.pdf)

português (PT) (560.45 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/pt/documents/overview/rituzena-epar-summary-public_pt.pdf)

slovenčina (SK) (626.1 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/sk/documents/overview/rituzena-epar-summary-public_sk.pdf)

slovenščina (SL) (618.76 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/sl/documents/overview/rituzena-epar-summary-public_sl.pdf)

Suomi (FI) (557.21 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/fi/documents/overview/rituzena-epar-summary-public_fi.pdf)

svenska (SV) (557.5 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

26/09/2017

[View](/sv/documents/overview/rituzena-epar-summary-public_sv.pdf)

## Product information

Rituzena : EPAR - Product Information

English (EN) (1.89 MB - PDF)

**First published:** 15/08/2017

**Last updated:** 18/02/2019

[View](/en/documents/product-information/rituzena-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-405)

български (BG) (3.93 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/bg/documents/product-information/rituzena-epar-product-information_bg.pdf)

español (ES) (1.95 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/es/documents/product-information/rituzena-epar-product-information_es.pdf)

čeština (CS) (3.28 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/cs/documents/product-information/rituzena-epar-product-information_cs.pdf)

dansk (DA) (1.9 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/da/documents/product-information/rituzena-epar-product-information_da.pdf)

Deutsch (DE) (2.01 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/de/documents/product-information/rituzena-epar-product-information_de.pdf)

eesti keel (ET) (1.9 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/et/documents/product-information/rituzena-epar-product-information_et.pdf)

ελληνικά (EL) (4.15 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/el/documents/product-information/rituzena-epar-product-information_el.pdf)

français (FR) (1.96 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/fr/documents/product-information/rituzena-epar-product-information_fr.pdf)

hrvatski (HR) (2.06 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/hr/documents/product-information/rituzena-epar-product-information_hr.pdf)

íslenska (IS) (1.93 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/is/documents/product-information/rituzena-epar-product-information_is.pdf)

italiano (IT) (1.92 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/it/documents/product-information/rituzena-epar-product-information_it.pdf)

latviešu valoda (LV) (3.44 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/lv/documents/product-information/rituzena-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.21 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/lt/documents/product-information/rituzena-epar-product-information_lt.pdf)

magyar (HU) (3.29 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/hu/documents/product-information/rituzena-epar-product-information_hu.pdf)

Malti (MT) (3.47 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/mt/documents/product-information/rituzena-epar-product-information_mt.pdf)

Nederlands (NL) (1.88 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/nl/documents/product-information/rituzena-epar-product-information_nl.pdf)

norsk (NO) (1.86 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/no/documents/product-information/rituzena-epar-product-information_no.pdf)

polski (PL) (3.59 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/pl/documents/product-information/rituzena-epar-product-information_pl.pdf)

português (PT) (1.88 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/pt/documents/product-information/rituzena-epar-product-information_pt.pdf)

română (RO) (2.2 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/ro/documents/product-information/rituzena-epar-product-information_ro.pdf)

slovenčina (SK) (3.28 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/sk/documents/product-information/rituzena-epar-product-information_sk.pdf)

slovenščina (SL) (3.14 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/sl/documents/product-information/rituzena-epar-product-information_sl.pdf)

Suomi (FI) (2 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/fi/documents/product-information/rituzena-epar-product-information_fi.pdf)

svenska (SV) (1.87 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

18/02/2019

[View](/sv/documents/product-information/rituzena-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IG/1053/G 28/01/2019

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rituzena : EPAR - All Authorised presentations

English (EN) (496.13 KB - PDF)

**First published:** 15/08/2017

**Last updated:** 17/01/2018

[View](/en/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-105)

български (BG) (529.93 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/bg/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_bg.pdf)

español (ES) (496.94 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/es/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_es.pdf)

čeština (CS) (551.19 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/cs/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (498.61 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/da/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (497.59 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/de/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (495.61 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/et/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (529.43 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/el/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_el.pdf)

français (FR) (496.82 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/fr/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (525.39 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/hr/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (497.75 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/is/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_is.pdf)

italiano (IT) (496.42 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/it/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (564.99 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/lv/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (524.79 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/lt/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (522.9 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/hu/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (540.43 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/mt/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (496.94 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/nl/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (497.86 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/no/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_no.pdf)

polski (PL) (539.62 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/pl/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_pl.pdf)

português (PT) (497.83 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/pt/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_pt.pdf)

română (RO) (526.98 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/ro/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (549.83 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/sk/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (534.53 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/sl/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (495.98 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/fi/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (497.12 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

17/01/2018

[View](/sv/documents/all-authorised-presentations/rituzena-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rituzena (previously Tuxella) Active substance rituximab International non-proprietary name (INN) or common name rituximab Therapeutic area (MeSH)

- Lymphoma, Non-Hodgkin
- Microscopic Polyangiitis
- Leukemia, Lymphocytic, Chronic, B-Cell
- Wegener Granulomatosis

Anatomical therapeutic chemical (ATC) code L01XC02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Rituzena is indicated in adults for the following indications:

Non-Hodgkin's lymphoma (NHL)

- Rituzena is indicated for the treatment of previously untreated patients with stage III IV follicular lymphoma in combination with chemotherapy.
- Rituzena monotherapy is indicated for treatment of patients with stage III IV follicular lymphoma who are chemo resistant or are in their second or subsequent relapse after chemotherapy.
- Rituzena is indicated for the treatment of patients with CD20 positive diffuse large B cell non Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.

Chronic lymphocytic leukaemia (CLL)

- Rituzena in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including Rituzenaor patients refractory to previous Rituzena plus chemotherapy.

Granulomatosis with polyangiitis and microscopic polyangiitis

- Rituzena, in combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).

## Authorisation details

EMA product number EMEA/H/C/004724

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Celltrion Healthcare Hungary Kft.

1062 Budapest

Opinion adopted 18/05/2017 Marketing authorisation issued 13/07/2017 Withdrawal of marketing authorisation 10/04/2019 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rituzena (previously Tuxella) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (630.71 KB - PDF)

**First published:** 26/09/2017

**Last updated:** 18/02/2019

[View](/en/documents/procedural-steps-after/rituzena-previously-tuxella-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Rituzena : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/421811/2017

English (EN) (9.54 MB - PDF)

**First published:** 15/08/2017

**Last updated:** 15/08/2017

[View](/en/documents/assessment-report/rituzena-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tuxella

Adopted

Reference Number: EMA/CHMP/307683/2017

English (EN) (532.16 KB - PDF)

**First published:** 19/05/2017

**Last updated:** 19/05/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tuxella_en.pdf)

#### News on Rituzena (previously Tuxella)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 May 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-may-2017) 19/05/2017

#### More information on Rituzena

Public statement on Rituzena: Withdrawal of the marketing authorisation in the European Union

Reference Number: EMA/290565/2019

English (EN) (108.12 KB - PDF)

**First published:** 08/07/2019

[View](/en/documents/public-statement/public-statement-rituzena-withdrawal-marketing-authorisation-european-union_en.pdf)

#### Related content

- [Biosimilar medicines](/en/human-regulatory/overview/biosimilar-medicines)

**This page was last updated on** 08/07/2019

## Share this page

[Back to top](#main-content)